Loading...

Please wait

Podcast

Loading...

OndaCast© 2026 OndaCast. All rights reserved.

Help Contact Terms Privacy Copyright DMCA About Radio Guide Embed Player

Waves Explore Library Vibes Podcasts Audiobooks

The IMID Forum - Podcast | OndaCast

Podcast

Back to Podcasts

The IMID Forum

Podcast ShowPodcasten

The IMID Forum

ByThe Immune-Mediated Inflammatory Disease Forum

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered a retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab

386 episodes•0 subscribers•0 Total Listens

Episode Playlist

50 episodes

Discussing RA: Insights into Filgotinib and Tofacitinib in RA

Dec 18, 2024•—

Discussing RA: Insights into Filgotinib and Tofacitinib in RA

Discussing RA: Insights into sustained DMARD-free remission and barriers to CAR T-cell therapy

Jan 22, 2025•—

Discussing RA: Insights into sustained DMARD-free remission and barriers to CAR T-cell therapy

Author Interview: Professor Denis McGonagle, 2025

Feb 5, 2025•—

Author Interview: Professor Denis McGonagle, 2025

Discussing RA: Baricitinib dose reduction and switching to bDMARDs vs JAKis

Feb 26, 2025•—

Discussing RA: Baricitinib dose reduction and switching to bDMARDs vs JAKis

Discussing axSpA: Long-term safety and efficacy of Bimekizumab results from BE-AGILE & BE-MOBILE 1/2

Feb 26, 2025•—

Discussing axSpA: Long-term safety and efficacy of Bimekizumab results from BE-AGILE & BE-MOBILE 1/2

Discussing PsA: Bimekizumab improves patient-reported outcomes and work productivity

Mar 5, 2025•—

Discussing PsA: Bimekizumab improves patient-reported outcomes and work productivity

Author Interview: Professor Phillip Helliwell, 2025

Mar 12, 2025•—

Author Interview: Professor Phillip Helliwell, 2025

Author Interview: Professor Phillip Helliwell, March 2025

Mar 19, 2025•—

Author Interview: Professor Phillip Helliwell, March 2025

Discussing RA: Pain reduction & choosing second-line DMARDs after unresponsive first-line DMARDs

Mar 26, 2025•—

Discussing RA: Pain reduction & choosing second-line DMARDs after unresponsive first-line DMARDs

Discussing PsA: JAKi Comparative safety & Burden and determinants of multi‑b/tsDMARD failure in PsA

Apr 2, 2025•—

Discussing PsA: JAKi Comparative safety & Burden and determinants of multi‑b/tsDMARD failure in PsA

Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA

Apr 16, 2025•—

Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA

Discussing RA: MACE, VTE, and malignancy in filgotinib RA and UC patients, and MACE related to JAKis

May 1, 2025•—

Discussing RA: MACE, VTE, and malignancy in filgotinib RA and UC patients, and MACE related to JAKis

Discussing axSpA: JAKi cycling and long-term safety of bimekizumab in patients with axSpA or PsA

May 8, 2025•—

Discussing axSpA: JAKi cycling and long-term safety of bimekizumab in patients with axSpA or PsA

Author Interview: Dr Saqr Alsakarneh, May 2025

May 22, 2025•—

Author Interview: Dr Saqr Alsakarneh, May 2025

Webinar Highlights Podcast: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs

May 28, 2025•—

Webinar Highlights Podcast: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs

Podcast: AuToDeCRA, June 2025

Jun 4, 2025•—

Podcast: AuToDeCRA, June 2025

Discussing RA: MACE in RA, data from the "JAK-pot" study, and combination therapy in MTX-IR RA

Jun 5, 2025•—

Discussing RA: MACE in RA, data from the "JAK-pot" study, and combination therapy in MTX-IR RA

EULAR 2025 Preview Podcast

Jun 9, 2025•—

EULAR 2025 Preview Podcast

EULAR 2025 Highlights: Day 1

Jun 11, 2025•—

EULAR 2025 Highlights: Day 1

EULAR 2025 Highlights: Day 2

Jun 12, 2025•—

EULAR 2025 Highlights: Day 2

Discussing PsA: Real-world data on biologic switching and the development of EMMs

Jun 12, 2025•—

Discussing PsA: Real-world data on biologic switching and the development of EMMs

EULAR 2025 Highlights: Day 3

Jun 13, 2025•—

EULAR 2025 Highlights: Day 3

EULAR 2025 Highlights: Day 4

Jun 14, 2025•—

EULAR 2025 Highlights: Day 4

Discussing RA: Impact of TOF on BMI, UPA monotherapy in MTX-IRs, and JAKis vs TNFis treatment

Jun 26, 2025•—

Discussing RA: Impact of TOF on BMI, UPA monotherapy in MTX-IRs, and JAKis vs TNFis treatment

EULAR 2025 Review Podcast

Jul 2, 2025•—

EULAR 2025 Review Podcast

Difficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash

Jul 3, 2025•—

Difficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash

Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA

Jul 10, 2025•—

Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA

Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

Jul 31, 2025•—

Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

Aug 7, 2025•—

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

Aug 14, 2025•—

Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

Aug 28, 2025•—

Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

Sep 4, 2025•—

Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

Sep 18, 2025•—

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

Sep 25, 2025•—

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

Author Interview: Doctor David Kellner, September 2025

Oct 2, 2025•—

Author Interview: Doctor David Kellner, September 2025

Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies

Oct 9, 2025•—

Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies

ACR 2025 Preview Podcast

Oct 22, 2025•—

ACR 2025 Preview Podcast

ACR Daily Highlights: Day 1

Oct 26, 2025•—

ACR Daily Highlights: Day 1

ACR Daily Highlights: Day 2

Oct 27, 2025•—

ACR Daily Highlights: Day 2

Pathways Modulating IMIDs: Webinar Highlights Podcast

Oct 28, 2025•—

Pathways Modulating IMIDs: Webinar Highlights Podcast

ACR Daily Highlights: Day 3

Oct 28, 2025•—

ACR Daily Highlights: Day 3

ACR Daily Highlights Day 4

Oct 29, 2025•—

ACR Daily Highlights Day 4

ACR 2025 Review Podcast

Nov 5, 2025•—

ACR 2025 Review Podcast

Discussing RA: Long-term management of elderly patients with RA treated with tocilizumab

Nov 6, 2025•—

Discussing RA: Long-term management of elderly patients with RA treated with tocilizumab

Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis

Nov 13, 2025•—

Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis

Webinar Highlights: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs: Part 2

Nov 16, 2025•—

Webinar Highlights: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs: Part 2

Author Interview: Professor Filip Rob, 2025

Nov 20, 2025•—

Author Interview: Professor Filip Rob, 2025

Discussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA

Nov 27, 2025•—

Discussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA

Discussing PsA: Uveitis risk and treatment sequencing outcomes in axSpa and PsA

Dec 4, 2025•—

Discussing PsA: Uveitis risk and treatment sequencing outcomes in axSpa and PsA

Discussing axSpA: Real-world outcomes for patients with axSpA receiving SC infliximab

Dec 11, 2025•—

Discussing axSpA: Real-world outcomes for patients with axSpA receiving SC infliximab

You May Also Like

OndaCast© 2026 OndaCast. All rights reserved.

Help Contact Terms Privacy Copyright DMCA About Radio Guide Embed Player

Waves Explore Library Vibes Podcasts Audiobooks